Amgen And UCB Present Positive Data At ENDO 2016 Comparing Romosozumab With Teriparatide

In Phase 3 Open-Label STRUCTURE Study Postmenopausal Women With Osteoporosis Transitioning From Oral Bisphosphonates to Romosozumab Experienced Consistent and Significant Gains in Bone Mass and Estimated Strength Over Teriparatide



Amgen - Investors - RSS Content